These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17346156)

  • 1. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
    Xu J; Peng H; Zhang JT
    Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
    Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
    PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2: structure, function and role in drug response.
    Polgar O; Robey RW; Bates SE
    Expert Opin Drug Metab Toxicol; 2008 Jan; 4(1):1-15. PubMed ID: 18370855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
    Ejendal KF; Hrycyna CA
    Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
    Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
    Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
    Ni Z; Bikadi Z; Rosenberg MF; Mao Q
    Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.
    Wang DS; Patel A; Sim HM; Zhang YK; Wang YJ; Kathawala RJ; Zhang H; Talele TT; Ambudkar SV; Xu RH; Chen ZS
    J Cell Biochem; 2014 Aug; 115(8):1381-91. PubMed ID: 24939447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.
    Peng H; Qi J; Dong Z; Zhang JT
    PLoS One; 2010 Dec; 5(12):e15276. PubMed ID: 21151870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance.
    Saito H; Hirano H; Ishikawa T
    Mini Rev Med Chem; 2007 Oct; 7(10):1009-18. PubMed ID: 17979803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pharmacology of ABCG2 and its role in chemoresistance.
    Stacy AE; Jansson PJ; Richardson DR
    Mol Pharmacol; 2013 Nov; 84(5):655-69. PubMed ID: 24021215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer.
    Hasanabady MH; Kalalinia F
    J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin.
    Chearwae W; Shukla S; Limtrakul P; Ambudkar SV
    Mol Cancer Ther; 2006 Aug; 5(8):1995-2006. PubMed ID: 16928820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
    Westover D; Li F
    J Exp Clin Cancer Res; 2015 Dec; 34():159. PubMed ID: 26714461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
    Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
    Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.